About

About Meridian Therapeutics

Meridian Therapeutics is early-stage biopharma company developing a new myeloma vaccine (Myelovax) to treat a broad range of cancers, with an initial focus on multiple myeloma. While many myeloma therapies today can reduce or eliminate the myeloma tumor burden in patients, few therapies are able to maintain that response over a long period of time to achieve a complete or functional cure.

Myelovax has the potential to lengthen remission using the power of the immune system to maintain response to therapy.

In a Phase I trials at Johns Hopkins University, Myelovax generated broad immune responses that persists over time and dramatically extended both Progression Free Survival and Overall Survival in patients, with almost no adverse events and no additional therapy.